Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1113

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1113
---
 research centers and pharmaceutical companies, focusing on rare disease, cancer diagnosis and other opportunities for clinical trials; it is expected that the investments required for these activities will be leveraged by non-dilutive funding instruments to de-risk individual projects and product development routes,

    ●
    Work to develop long-term strategic partnerships with clinical organizations, research centers and pharmaceutical companies to advance existing research in multi-modal analysis and open potential revenue streams;

    ●
    Develop Renovaro Cube’s multi-modal, multi-omics platform architecture and first prototypes, with the goal of providing integrated multi-modal solutions that would be sold as a fully deployed and fully supported solution, subject to compliance with regulatory standards for hosting and support and for production of algorithms being deployed in a clinical environment;

    ●
    Build Renovaro Cube’s service and support models for its AI platform;

    ●
    Build or lease a “supercomputer” that will be utilized for processing genomic data, the training of algorithms and the development of Renovaro Cube’s solutions;

    ●
    Continue business development across key territories in the Europe, Middle East, and Africa (“EMEA”) region, starting in the United Kingdom, the Netherlands and Germany, under the management of in-country managers supported by centralized teams in Amsterdam and London and progress to rolling out in the US leveraging the Lunai US based staff;

    ●
    Deploy a sequencing lab in the EMEA region that will allow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and

    ●
    
    Expand its team to include biomedical scientists,
    data scientists, machine-learning engineers, specialized medical doctors (oncologist, geneticist), high-performance-computer engineers
    and software engineers.
     
    ● Renovaro
    Cube plans to establish a state-of-the-art fully certified (CLIA and ISO standards) service laboratories to perform liquid biopsies in
    a multi-omic approach for third parties (primarily research and academic institutes) and provide data analysis at the same time. This
    activity serves two important goals:
     
     ● It
    provides immediate revenues for the company providing a superior service for multi-omic sequencing servicing using Oxford Nanopore
    Technologies for an attractive pricing and high-end services also applicable for liquid biopsies.
     
    ● The Cube
    needs data to expand the indications, application and improve the capabilities of the system. Acquiring this data is a lengthy and
    expensive